Esophageal cancer (EC) and gastric cancer (GC) are fatal cancers with a relatively late age of onset. Age is a negative risk factor for survival in many cancers and our aim was to analyze age-specific survival in EC and GC using the recently updated NORDCAN database. NORDCAN data originate from the Danish, Finnish, Norwegian, and Swedish nationwide cancer registries covering years 1972 through 2021 inviting for comparison of 50-year survival trends between the countries. Relative 1- and 5-year survival and 5/1-year conditional survival (i.e., survival in those who were alive in Year 1 to survive additional 4 years) were analyzed. Survival in EC showed large gains for patients below age 80 years, 5-year survival in Norwegian men reaching 30% and in women over 30% but for 80-89 year old survival remained at 10%. In contrast, hardly any gain was seen among the 80-89 year patients for 1-year survival and small gains in 5 year and 5/1-year survival. Survival gaps between age-groups increased over time. For GC there was also a clear age-related negative survival gradient but the survival gaps between the age groups did not widen over time; Norwegian male and female 5-year survival for 80-89 year old was about 20%. The age-specific survival difference in GC arose in Year 1 and did not essentially increase in 5-year survival. While there were differences in survival improvements between the countries, poor survival of the 80-89 year old patients was shared by all of them. To conclude, survival has improved steadily in younger GC and EC patients in most Nordic countries. While the 80-89 year old population accounts for nearly a quarter of all patients and their poor survival depressed overall survival, which can therefore be increased further by improving diagnostics, treatment and care of elderly EC and GC patients.

Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Cancer Gene Therapy Group Translational Immunology Research Program University of Helsinki Helsinki Finland

Comprehensive Cancer Center Helsinki University Hospital Helsinki Finland

Department of Surgery University Hospital Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Urology Helsinki University Hospital and University of Helsinki Helsinki Finland

Division of Cancer Epidemiology German Cancer Research Center Heidelberg Germany

Division of Pediatric Neurooncology German Cancer Research Center Heidelberg Germany

Hopp Children's Cancer Center Heidelberg Germany

Zobrazit více v PubMed

Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000‐14 (CONCORD‐3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population‐based registries in 71 countries. Lancet. 2018;391(10125):1023‐1075. PubMed PMC

Hemminki J, Försti A, Hemminki A, Hemminki K. Survival trends in solid cancers in the Nordic countries through 50 years. Eur J Cancer. 2022;175:77‐85. PubMed

Hemminki K, Tichanek F, Försti A, Hemminki O, Hemminki A. Survival in gastric and esophageal cancers in the Nordic countries through a half century. Cancer Med. 2023;12(9):10212‐10221. PubMed PMC

Klint A, Engholm G, Storm HH, et al. Trends in survival of patients diagnosed with cancer of the digestive organs in the Nordic countries 1964‐2003 followed up to the end of 2006. Acta Oncol. 2010;49(5):578‐607. PubMed

Maret‐Ouda J, Markar SR, Lagergren J. Gastroesophageal reflux disease: a review. JAMA. 2020;324(24):2536‐2547. PubMed

Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635‐648. PubMed

Allum W, Lordick F, Alsina M, et al. ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer. Crit Rev Oncol Hematol. 2018;122:179‐193. PubMed

Jeremiasen M, Linder G, Hedberg J, et al. Improvements in esophageal and gastric cancer care in Sweden‐population‐based results 2007‐2016 from a national quality register. Dis Esophagus. 2020;33(3):1‐9. PubMed PMC

Obermannová R, Alsina M, Cervantes A, et al. Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow‐up. Ann Oncol. 2022;33(10):992‐1004. PubMed

Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow‐up. Ann Oncol. 2022;33(10):1005‐1020. PubMed

De Angelis R, Minicozzi P, Sant M, et al. Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000‐2007: results of EUROCARE‐5 population‐based study. Eur J Cancer. 2015;51(15):2254‐2268. PubMed

Withrow DR, Nicholson BD, Morris EJA, Wong ML, Pilleron S. Age‐related differences in cancer relative survival in the United States: a SEER‐18 analysis. Int J Cancer. 2023;152(11):2283‐2291. PubMed

Pilleron S, Charvat H, Araghi M, et al. Age disparities in stage‐specific colon cancer survival across seven countries: An international cancer benchmarking partnership SURVMARK‐2 population‐based study. Int J Cancer. 2021;148(7):1575‐1585. PubMed

Haase KR, Sattar S, Pilleron S, et al. A scoping review of ageism towards older adults in cancer care. J Geriatr Oncol. 2023;14(1):101385. PubMed

Pilleron S, Soto‐Perez‐de‐Celis E, Vignat J, et al. Estimated global cancer incidence in the oldest adults in 2018 and projections to 2050. Int J Cancer. 2021;148(3):601‐608. PubMed PMC

Engholm G, Ferlay J, Christensen N, et al. NORDCAN–a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49(5):725‐736. PubMed

Pukkala E, Engholm G, Hojsgaard Schmidt LK, et al. Nordic cancer registries–an overview of their procedures and data comparability. Acta Oncol. 2018;57:440‐455. PubMed

Larønningen SAG, Bray F, Engholm G, et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 9.3. 2023.

Brenner H, Gefeller O, Hakulinen T. Period analysis for ‘up‐to‐date’ cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer. 2004;40(3):326‐335. PubMed

Lundberg FE, Andersson TM, Lambe M, et al. Trends in cancer survival in the Nordic countries 1990‐2016: the NORDCAN survival studies. Acta Oncol. 2020;59(11):1266‐1274. PubMed

Brenner H, Arndt V, Gefeller O, Hakulinen T. An alternative approach to age adjustment of cancer survival rates. Eur J Cancer. 2004;40(15):2317‐2322. PubMed

Tichanek F, Försti A, Liska V, Hemminki A, Hemminki K. Survival in colon, rectal and small intestinal cancers in the Nordic countries through a half century. Cancers. 2023;15(3), 1‐13. PubMed PMC

Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high‐income countries 1995‐2014 (ICBP SURVMARK‐2): a population‐based study. Lancet Oncol. 2019;20(11):1493‐1505. PubMed PMC

Cheng Z, Johar A, Gottlieb‐Vedi E, Nilsson M, Lagergren J, Lagergren P. Impact of co‐morbidity on reoperation or death within 90 days of surgery for oesophageal cancer. BJS Open. 2021;5(1):1‐5. PubMed PMC

Foukakis T, Lundell L, Gubanski M, Lind PA. Advances in the treatment of patients with gastric adenocarcinoma. Acta Oncol. 2007;46(3):277‐285. PubMed

Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 2013;63(4):232‐248. PubMed

Probst HB, Hussain ZB, Andersen O. Cancer patient pathways in Denmark as a joint effort between bureaucrats, health professionals and politicians–.a national Danish project. Health Policy. 2012;105(1):65‐70. PubMed

Arnold M, Morgan E, Bardot A, et al. International variation in oesophageal and gastric cancer survival 2012‐2014: differences by histological subtype and stage at diagnosis (an ICBP SURVMARK‐2 population‐based study). Gut. 2021;71:gutjnl‐2021‐325266‐gutjnl‐2021‐321543. PubMed

Zakko L, Lutzke L, Wang KK. Screening and preventive strategies in esophagogastric cancer. Surg Oncol Clin N Am. 2017;26(2):163‐178. PubMed PMC

An L, Zheng R, Zeng H, et al. The survival of esophageal cancer by subtype in China with comparison to the United States. Int J Cancer. 2023;152(2):151‐161. PubMed

De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE‐5–a population‐based study. Lancet Oncol. 2014;15(1):23‐34. PubMed

Schuurman MS, Lemmens V, Portielje JEA, van der Aa MA, Visser O, Dinmohamed AG. The cancer burden in the oldest‐old: increasing numbers and disparities–a nationwide study in The Netherlands, 1990 to 2019. Int J Cancer. 2024;154(2):261‐272. PubMed

Ludmir EB, Mainwaring W, Lin TA, et al. Factors associated with age disparities among cancer clinical trial participants. JAMA Oncol. 2019;5(12):1769‐1773. PubMed PMC